ClinicalTrials.gg
Active, not recruitingNCT05000710CORAL-LungUpdated Dec 5, 2024

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

A Phase 2 interventional study of Durvalumab and Tremelimumab in Metastatic or Locally Advanced NSCLC, sponsored by Sheba Medical Center. Active, not recruiting at 1 site in Israel. Per ClinicalTrials.gov, last updated 2024-12-05.

Sponsored by Sheba Medical Center · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Neoplasm Metastasis with a site in Israel — 14 open to participants now, 33 under way, 17 of them phase 3. Neoplasm Metastasis · Israel.

Planned enrollment
93rd of 108
29 · median 301
Started
2021
with 10 others
Phase 2
24 of 112
none open now
Primary completion
2026-12
later than 11 of 32 live
Registered
87th of 112
by date

Among the 112 studies in Neoplasm Metastasis with a site in Israel, this one is the 93rd largest by planned enrollment of the 108 interventional ones that give a count, is one of 11 that started in 2021, is one of 24 in phase 2, reaches primary completion later than 11 of the 32 other live ones, and was the 87th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

14 of the 112 studies in Neoplasm Metastasis with a site in Israel are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Neoplasm Metastasis with a site in Israel, or all of them as a file.
02

Study summary

This is an open-label, single-arm, phase 2a trial with a safety run-in cohort followed by a Simon two-step design expansion cohort, of two checkpoint blockage treatments and radiotherapy in the treatment of locally advanced or metastatic NSCLC who have failed first-line immunotherapy (alone or as a combination regimen with chemotherapy).

Study objectives:

Objective of the safety run-in phase:

  • To evaluate safety of the triple combination of irradiation -Durvalumab - Tremelimumab

Co-Primary objectives of the entire study:

  • To evaluate safety of the triple combination (as for the run-in phase).
  • To evaluate response rate on study drug compared to historical data of response to first-line platinum-doublet chemotherapy and 2nd-line docetaxel.

Secondary objective:

  • To evaluate PFS and OS compared to historical data .

Exploratory objectives:

  • Examine the mechanism of resistance to first-line immunotherapy .
  • Examine the immune response in irradiation -Durvalumab - Tremelimumab treated patients and identify potential predictors of clinical benefit.
Read the detailed description

A cycle is defined as 28 days. Eligible patients who have a radiologically confirmed progressive disease on first line Immunotherapy treatment will receive an intravenous injection of 300 mg Tremelimumab at D1 and 12 weeks later a second dose of 300 mg tremelimumab, and an intravenous injections of 1500 mg Durvalumab q4w (starting from D1) . Treatment duration is until objective radiological disease progression as per RECIST 1.1 assessed by the local radiologist, and as long as the patients are benefiting from treatment according to the investigator's opinion and they do not meet any other discontinuation criteria.

21 days after the first immunotherapy treatment, a radiotherapy course of 11 fractions of 3 Gy (total of 33 Gy) will be administrated to metastatic or primary lesion/s over two weeks and one day. The second durvalumab treatment will be administered at the beginning of the 2nd week of radiotherapy, one week after radiotherapy start day.

Following patients consent, a fresh biopsy specimen will be obtained (if not previously obtained after PD) for correlative studies, preferably from site of disease progression on first line immunotherapy.

In addition, tissue samples will be obtained from both existing archived biopsy (diagnostic specimen), if available. An optional newly biopsied tissue sample will be taken 20 weeks after initiation of study treatment and at the time of progression on study treatment. Biopsy at PD is mandatory if can be performed with no significant risk.

Blood and microbiome samples for correlative studies will be taken at predefined intervals, to explore predictive biomarkers for clinical efficacy, determine pharmacodynamic effects on immune cells, determine immune response signatures.

Tumor imaging should be acquired by CT and include the chest, abdomen, and pelvis with and without IV contrast and with oral contrast. CT should be performed at baseline and every 8 weeks until objective radiological disease progression assessed as per RECIST 1.1.

Patients who have discontinued treatment should be seen at end of treatment and 28 days post discontinuation for the evaluations outlined in the study schedule. Patients will be contacted every 90 days following discontinuation visit to capture survival status.

Any patient who discontinues study treatment for reasons other than objective radiological progression should continue to undergo scheduled objective tumor assessments according to the study schedule in order to assess objective radiological progression of disease.

03

Conditions studied

  • Metastatic or Locally Advanced NSCLC

Browse trials for

Keywords

  • checkpoint inhibitors
  • treatment-related toxicity leading to treatment discontinuation
  • RECIST 1.1
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced or (stage 3 or stage 4) proven NSCLC patients not candidate for curative - intent treatment.
  • Have been previously treated with one prior immunotherapy (i.e. anti-PD1 or antibodies, with or without chemotherapy) for advanced or metastatic NSCLC. Additional systemic treatment lines for metastatic disease are not allowed.

    1. Previous chemotherapy treatment lines administered earlier for non-metastatic disease (adjuvant, ) are allowed if completed more than six months prior to diagnosis of advanced disease.
    2. Patients recurring within six months of end of adjuvant/maintenance immunotherapy (e.g. durvalumab post-chemorads) are eligible for the study if no additional systemic treatment was administered prior to enrollment on the study (this situation is considered equivalent to progression on immunotherapy).
  • Documented radiologic progression on immunotherapy. Minimal treatment time on first-line immunotherapy is 12 weeks. Progressive disease needs to be confirmed by a repeat scan performed at least 4 weeks after the first objective progression.
  • Availability of at least 1 disease site not previously irradiated to serve as a target for radiotherapy. However, a disease site that progressed after having received previously radiotherapy can serve as a radiotherapy target on this trial.
  • Availability of at least 1 not previously irradiated that is not planned to be irradiated during the study and measurable as defined by the (RECIST) 1.1.
  • Availability of at least 1 disease site suitable for procedure (unless the patient has had a biopsy postprogression on immunotherapy), preferably, at site of disease progression on immunotherapy. Fine needle aspirate , ascites or effusion specimens are not acceptable . Selected sites for biopsy can serve afterwards as radiotherapy targets.
  • Patient must have had a treatment free interval of at least 4 weeks from any prior therapy (includes major surgery) before starting of study drugs.

Minor surgical procedures (as defined by the investigator): 7 post-operative days.

Patients who receive palliative radiation for nontarget tumour lesions need a of 7 days.

  • Have an performance status of 0 or 1 and a minimum of 12 weeks.
  • Have adequate normal organ and marrow function, including the following:

    1. ≥1.0 × 109/L.
    2. count ≥ 75× 109/L.
    3. ≥ 9.0 g/dL.
    4. (ALT) and Aspartate aminotransferase (AST) ≤ 2.5 × the (ULN) if no demonstrable liver metastases or ≤ 5 × ULN in the presence of liver metastases.
    5. Total (TBL) ≤ 1.5 × ULN or for patients with documented/suspected Gilbert's disease, bilirubin ≤ 2 × ULN.
    6. Creatinine ≤ 1.5 × ULN or ≥ 40 mL/min (creatinine clearance can be measured or calculated by Cockcroft and Gault equation; measurement/calculation is only required when creatinine is >1.5 × ULN).
  • Body weight >30kg
  • Be willing and able to provide written for the trial prior to any study specific procedures.The subject must also provide consent for correlative translational study.
  • Male or female subjects who are ≥ 18 years of age on the day of signing the informed consent.
  • Evidence of status or negative urinary or serum pregnancy test for female pre-menopausal patients. Female subjects of should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

    • Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
    • Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
  • Female subjects of childbearing potential must be willing to use an adequate method of for the course of the study through 180 days after the last dose of study medication.
  • Male subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 180 days after the last dose of study therapy.

Exclusion criteria

Exclusion Criteria:

  • Progression (as defined by 1.1) within 12 weeks from initiation of immunotherapy (this criteria aims at exclusion of patients with primary resistance; this study focuses on acquired resistance).
  • Prior exposure to anti , including tremelimumab
  • All potential radiotherapy targets involve high risk of significant toxicity.
  • Mixed response to immunotherapy, where growth occurred only in a single lesion that is amendable to curative-intent radiotherapy (this criteria aims to exclude patients more likely to benefit from targeted radiotherapy to the growing mass and continuation of immunotherapy).
  • Any unresolved toxicity Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Physician.
  • Any prior immune-related adverse events grade 3 or higher (as per CTCAE version 5.0).
  • Known allergy or to any of the study drugs or any of the study drug
  • Progressing . Stable brain metastasis (based on at least two brain imaging tests with a 4 week interval or more) are allowed (including non-treated lesions) as long as there no requirement for due to the brain spread for ≥4 weeks prior to start of study treatment.
  • History of
  • Patients whose tumour samples are known to have activating mutations in the EGFR gene, translocations of the ALK gene, or rearrangement of the ROS1 gene that are indicated for treatment by approved TKI therapy are excluded.
  • or inflammatory disorders requiring systemic treatment during the year prior to study treatment including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis with the exception of diverticulosis, celiac disease (or other serious gastrointestinal chronic conditions associated with diarrhea), systemic lupus erythematosus, Sarcoidosis syndrome, Wegener syndrome (granulomatosis with polyangiitis), Graves' disease, rheumatoid arthritis, hypophysitis, uveitis. The following are exceptions to this criterion: Patients with vitiglio or alopecia, Patients with hypothyroidism (eg, following Hashimoto syndrome) and stable on hormone replacement not requiring systemic treatment, Psoriasis not requiring treatment. Additional exceptions are any chronic skin condition that does not require systemic therapy and patients with celiac disease controlled by diet alone. Patients without active disease in the last 5 years may be included but only after consultation with the study physician.
  • Current or prior use of medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion: Intranasal, inhaled, or topical steroids, or local steroid injections (e.g., intraarticular injection). Systemic corticosteroids at physiologic doses are allowed up to 10 mg/day of prednisone or its equivalent. Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication) are allowed.
  • Active infection with (known positive HBV surface antigen[HBsAg] result), or tuberculosis. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg are eligible.Patients positive for hepatitis C (HCV) antibody are eligible only if the polymerase chain reaction is negative for HCV RNA. Tuberculosis clinical evaluation includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice.
  • Known (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness.
  • Organ transplanted patients.
  • Any condition that, in the opinion of the Investigator, would interfere with the evaluation of IP or interpretation of patient safety or study results, including, but not limited to, uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written .
  • History of another primary except for: Malignancy treated with curative intent and with no known active disease ≥3 years before the first dose of IP and of low potential risk for recurrence, Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, adequately treated carcinoma in situ (breast DCIS, non-invasive cervical cancer, etc.) without evidence of disease. Patients with tumors with a very low risk of spread and recurrence that were treated successfully with a curative intent (e.g. resected local carcinoid tumor, recected low grade, non-muscle invasive bladder cancer) can be considered for inclusion based on decision of the study physician.
  • Receipt of within 30 days prior to the first dose of study drugs.
  • Have received treatment with an product or nonapproved use of a drug or device within 28 days prior to the initial dose of study drugs, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Female patients who are pregnant or breastfeeding.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (estimated)

Study arms

  • Experimental
    study arm

    Study treatments include: Durvalumab at D1 and q4w + Tremelimumab at C1D1 and C4D1. Radiotherapy 11 fractions (start at D21).

    Drug: Durvalumab · Drug: Tremelimumab · Radiation: Low dose irradiation

Interventions

  • Durvalumab administered IV over 60 minutes at a dose of 1500 mg every 4 weeks

    Also known as: Imfinzi, MEDI4736

  • Tremelimumab administered IV over 60 minutes at a dose of 300 mg , twice: at C1D1 and C4D1

  • RadiationLow dose irradiation

    21 days after the first immunotherapy treatment 11 fractions of 3 Gy will be administrated to metastatic or primary lesion/s over 2 weeks and one day

06

What researchers measure

Primary outcomes

  1. treatment-related toxicity leading to treatment discontinuation (TRTLTD), as assessed by CTC-AE version 5.0.

    number of patients with TRTLTD will be evaluated during the safety run-in phase

    Time frame: Approximately 2 years

  2. Incidence of Treatment-Emergent Adverse Events, as assessed by CTCAE version 5.0

    Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA, most updated version) terminology and presented in tables by System Organ Class (SOC) and Preferred Term (PT).

    Time frame: From day of subject's written consent until study termination, approximately 4.5 years

  3. Response rate on study treatment (according to investigator assessment, per RECIST 1.1)

    Proportion of subjects showing best overall response of complete response (CR) or partial response (PR)

    Time frame: Up to 5 months from treatment initiation, approximately 4.5 years overall

Secondary outcomes

  1. PFS on study treatment (according to investigator assessement, per RECIST 1.1

    Duration of time from start of treatment to time of progression or death, whichever occurs first.

    Time frame: From first dose of immunotherapy until first progression, approximately 4.5 years

  2. Overall survival (OS)

    Duration of time from diagnosis until death (or date of last documentation of being alive). Survival data may be obtained via contact with the patient, patient's family, or through a review of the patient's notes, or through the use of public records.

    Time frame: From documented metastatic disease until death (or date of last documentation of being alive), approximately 4.5 years

  3. Change in biomarkers

    Blood, tumor and microbiome samples will be analyzed for various biomarkers. Initial biomarkers to be tested include proteins such as PDL-1, immune cell composition, cfDNA, microRNA proteomics and bacteria populations

    Time frame: 5 years

07

Study locations

1 site
08

References and documents

Publications

  • Frey B, Ruckert M, Weber J, Mayr X, Derer A, Lotter M, Bert C, Rodel F, Fietkau R, Gaipl US. Hypofractionated Irradiation Has Immune Stimulatory Potential and Induces a Timely Restricted Infiltration of Immune Cells in Colon Cancer Tumors. Front Immunol. 2017 Mar 8;8:231. doi: 10.3389/fimmu.2017.00231. eCollection 2017. PubMed 28337197 ↗
  • Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeno J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Ozguroglu M; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8. PubMed 28885881 ↗
  • Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, Klapproth K, Schakel K, Garbi N, Jager D, Weitz J, Schmitz-Winnenthal H, Hammerling GJ, Beckhove P. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013 Nov 11;24(5):589-602. doi: 10.1016/j.ccr.2013.09.014. Epub 2013 Oct 24. PubMed 24209604 ↗
  • Chajon E, Castelli J, Marsiglia H, De Crevoisier R. The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership. Crit Rev Oncol Hematol. 2017 Mar;111:124-132. doi: 10.1016/j.critrevonc.2017.01.017. Epub 2017 Feb 4. PubMed 28259287 ↗
  • McNamara MJ, Hilgart-Martiszus I, Barragan Echenique DM, Linch SN, Kasiewicz MJ, Redmond WL. Interferon-gamma Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade. Cancer Immunol Res. 2016 Aug;4(8):650-7. doi: 10.1158/2326-6066.CIR-16-0022. Epub 2016 Jun 4. PubMed 27262113 ↗
  • Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Berard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5. PubMed 26541610 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.

Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's planned 60 months is close to that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2021
First posted
Aug 11, 2021
StartActual
Dec 9, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05000710
Responsible party
Jair Bar, M.D., Ph.D. (Deputy Director, Institute of Oncology, Sheba Medical Center) — Principal investigator
First posted
Aug 11, 2021
Start date
Dec 9, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 5, 2024

Study contacts

Jair Bar, Dr
principal investigator · Shaba Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tremelimumab

Start the discussion